David K. Morris, Executive Vice President and Chief Financial Officer of Guardian Pharmacy Services, Inc. (GRDN), completed a sale of 187,855 shares of the company's Class A Common Stock on March 20, 2026. The transaction was executed at $29.6825 per share and totaled approximately $5,576,006.
Since the disposition, Guardian Pharmacy's stock has advanced to $37.57, trading close to its 52-week high of $38.12 and reflecting a 75.56% gain over the last 12 months. An InvestingPro analysis cited in company commentary indicates the stock appears overvalued at current levels when measured against Fair Value metrics.
Following the sale, Morris continues to hold a direct stake of 254,472 shares of Guardian Pharmacy Services. The sale was carried out pursuant to the Underwriting Agreement dated March 18, 2026, and the transaction record was signed on March 24, 2026, by Douglas Towns acting as Attorney-in-Fact on behalf of Morris.
The share transaction comes as Guardian Pharmacy reported fourth-quarter financial results that beat consensus estimates. The company posted revenue of $397.6 million versus the Street estimate of $390.0 million. Adjusted EBITDA for the quarter was $39.5 million, ahead of the $28.8 million consensus.
Following the earnings release, brokerages adjusted their outlooks. Truist Securities raised its price target for Guardian Pharmacy to $38 while maintaining a Buy rating. Raymond James increased its target to $40 and kept an Outperform rating, citing the company's robust vaccine program as part of its rationale.
Separately, Guardian Pharmacy completed an underwritten public offering of 6,900,000 shares of Class A common stock at $31 per share. The offering comprised 5,880,000 shares sold by certain stockholders and 1,020,000 newly issued shares from the company in a synthetic secondary transaction. The company used the net proceeds from its portion of the offering to repurchase the 1,020,000 newly issued shares, which were subsequently canceled.
Management indicated that the repurchase of the newly issued shares resulted in no net change to the total number of Class A shares outstanding following the offering. The underwriting agreement tied to the sale by Morris is dated March 18, 2026, and procedural signing on his behalf was completed on March 24, 2026.
Clear summary: Guardian Pharmacy Services CFO David K. Morris sold 187,855 Class A shares on March 20, 2026, for about $5.576 million under an underwriting agreement. The stock has since risen to $37.57, and the company recently beat Q4 revenue and adjusted EBITDA estimates. An underwritten offering of 6.9 million shares at $31 per share was completed; the company used proceeds to repurchase and cancel its newly issued portion, leaving Class A outstanding shares unchanged.